Travere Therapeutics, Inc. (TVTX) Stock
6 of the hedge funds AlphaScala tracks reported TVTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $104.14M. Company insiders reported 0 open-market buys and 49 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own TVTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.83M | $104.14M | -7% |
| D.E. Shaw David Shaw | 1.44M | $81.83M | +72% |
| Marshall Wace | 1.33M | $75.74M | +647% |
| Point72 Steve Cohen | 479K | $27.20M | NEW |
| Millennium Management Israel Englander | 85K | $4.81M | NEW |
| Citadel Ken Griffin | 38K | $2.18M | -70% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Travere Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 128.1K | $6.8M |
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 37.3K | $2.0M |
| Oct 15, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 78.4K | $4.3M |
| Sep 17, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 101.7K | $6.6M |
| Sep 17, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 6.8K | $442K |
| Sep 17, 26 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | SELL | 8.3K | $539K |
| Sep 16, 26 | Rote William E. | Chief Research Officer | SELL | 65.1K | $4.1M |
| Sep 16, 26 | Rote William E. | Chief Research Officer | SELL | 47.7K | $3.0M |
| Sep 16, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 99.7K | $6.3M |
| Sep 16, 26 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 96.1K | $6.1M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →TVTX price chart
Powered by TradingViewWhat does Travere Therapeutics, Inc. do?
Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases. The company's primary mission is to address unmet medical needs in patient populations that have few existing treatment options. Travere Therapeutics operates in the pharmaceutical sector, focusing predominantly on nephrology and hepatology. Its pipeline includes drug candidates aimed at treating complex conditions like focal segmental glomerulosclerosis (FSGS) and Alport syndrome, both of which are linked to kidney diseases. With a strong commitment to advancing scientific research and improving patient outcomes, Travere Therapeutics partners with healthcare professionals and scientists to drive innovation in niche medical areas. The company plays a significant role in the biotech industry, providing new avenues for treating challenging health issues that affect small populations. Travere's presence in the rare disease market underscores its significance as a leader in providing hope and solutions for patients who desperately need breakthrough therapeutics.